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Development of Animal Drugs for Market
Presented Before the Iowa Academy of Science, April 21 , 22, 1967
K. B. KERR, SC.D.
Director of Developmental Research
Salsbury Laboratories
Charles City, Iowa

The complexities of modem scientific knowledge have vastly increased
the requirements for the clearance of
an animal drug for market. All such
drugs, which include those for poultry, are subject to the regulations of
the Food and Drug Administration
(FDA). The data obtained in the development studies must convince the
FDA examiners that the drug is both
safe and effective. To accomplish this,
numerous disciplines are involved,
such as parasitology, microbiology,
pharmaceutical formulation, nutrition,
animal management, organic chemistry, analytical chemistry, biochemistry, pharmacology, pathology, veterinary medicine, chemical engineering,
and statistics. Thus, the desired product can only be obtained by a team
approach. In our laboratory there are
four teams involved; the first finds an
effective drug, the second evaluates
its safety, the third evaluates its action in field tests, and the fourth produces the drug in quantity.
Product development is expensive,
yet new products are essential to a dynamic industry. Because of the costs,
all product development must be
carefully evaluated by management.
The market is determined, selling
price estimated, and the cost of research, development, and production
evaluated. Only then can a decision

be made concerning the potential of
the product. Some products, such as
those for poultry, must be marketed at
a very low cost, for the total cost of
medication and vaccination should
not be greater than three cents per
broiler chicken.
The challenge of drug development
is that it is the result of someone's
idea. As the idea is developed, other
ideas occur so that one is working in
a thought-provoking environment and
continually subjected to the stimulus
of problem-solving. There is a great
satisfaction when the product is marketed.
The initial testing of a substance or
compound may be simply a blind
screen, that is, testing the material for
activity on the basis of its availability.
However, in the writer's experience,
he selected first those compounds
which, from their chemical structure
and from knowledge of the scientific
literature, he judged to be most likely
to have activity. The organic chemist
also enters into this picture, for he
may have conceived of a chemical,
synthesized it, and submitted it for
testing. Once some degree of activity
has been determined, then the biologist and chemist can work together in
molecule manipulation, that is, changing the position of a moiety or substituting other moieties on the basic
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structure. For example, when the
writer was doing this work and found
activity for organotin compounds as
anthelmintics, he examined 125 of
these compounds. The best of these
was selected for a product, and excellent patent coverage was obtained for
the series. Other biologists then tested
a number of the compounds for activity against other disease-causing organisms.
The next step is the establishment
of all ways in which the compound
may be used, i.e., for treatment, for
preventj_on, administered as a tablet, in
the feed, in the drinking water, or by
injection. Not only must the amount
be established, but also the length of
time it will be administered. Since
few · drugs are administered as the
compound per se, it is necessary to
formulate it into a product. If it is to
be a tablet, suitable binders or other
ingredients must be found. If it is to
be administered in drinking water, it
may have to be incorporated with
solubilizers or pH controlling agents.
A product to be mixed in feed usually
consists of the compound and some
suitable feed ingredient which will
permit thorough distribution in the
final feed. An injectable product must
not be more than transiently irritating. In each dosage form, the effectiveness of the product must be clearly defined.
The studies to this point have required a considerable quantity of compound. Usually the organic chemist
has been supplying it from syntheses
in his laboratory. This has provided
the opportunity to try different production procedures and from this experience he has reached a decision as
to the most economical method of pro-

duction in the chemical plant. This
work has also permitted better definition of the physical and chemical
properties and methods of purification. Identification of the contaminants which may be present is also
important.
At this point, another team takes
over the production of the compound.
This team consists of production chemists and chemical engineers who determine how to adapt the procedure
recommended by the organic chemists
to the production facilities. This is
usually done through a pilot plant
process where it is determined what
effects reaction conditions have upon
yield when pound batches of the
chemical are produced. The quality of
the chemical must be continually
checked. As experience is gained, the
type of equipment required for larger
batches and the economics of the
process are worked out. These studies
finally permit the definition of the
specifications for the compound, that
is, its purity, and physical and chemical characteristics for identification.
In our institution, analytical chemistry is tied in with the safety team.
These chemists have been involved in
developing a method of analysis and
the more specific the method, the better it is considered to be. Three methods of analysis may be necessary, one
for the compound itself, one for the
compound incorporated in the product, and one for the final dosage form
if that form is feed or drinking water.
The last method requires the greatest
sensitivity because the dosage may be
as low as 50 ug per gram of medium.
The final dosage form method of
analysis must also be studied for possible interfering substance, such as
11

other drugs which are used in feeds ,

which may be included by chance or
accident. This knowledge is very helpful in the quality control of the final
dosage form. The first two types of
methods are supplied to the quality
control section of the production team
and the third is made ready for the
eventual customer.
When methods and formulated
product are available, the analytical
chemist initiates stability studies on
the product and, if applicable, the
final dosage form in feed or drinking
water. These are subjected to various
environments and analyses made at
definite intervals over at least a sixmonth period to determine whether
changes in quantity have occurred.
Also, many feeds are pelleted, so it
must be shown that this process does
not change the content of the compound.
When sufficient compound is available and the dosage has been established, safety studies are initiated in
animals. The first of these are designed to determine the safety of the
product for the animals on which it is
to be used. The types of safety tests
which may be done are : acute toxicity, which are short-term; subacute
toxicity, which are ninety days in duration or for the lifetime of a shortlived animal ( broilers, turkeys );
chronic toxicity, which are two-year
tests; and reproduction tests to ensure that the compound has no effects
on this phase of life. In most of these
tests, it is desirable to determine the
maximum dose which has no harmful
effect ( the no-effect dose) and the
maximum tolerated dose, or that dose
which harms, but is not lethal.
Acute toxicity studies are done pri-

marily on compounds in products
which are used for treatment of disease and particularly those which will
be used for only a few days. This test
involves the determination of the single oral dose which will be lethal to
50 per cent of the test animals (LD 50 ) .
The acute toxicity of compounds to be
given to large animals is determined
in laboratory animals. The LD 50 is
used because it is the most easily reproduced and is actually established
by means of a statistical manipulation.
From this a therapeutic index is derived, that is, the ratio between the
LD 50 and the therapeutic dose. The
greater the ratio, the greater the probability of safety. It is also very helpful if one can determine by this test
the organs most affected by an excessive dosage.
The subacute toxicity test is of particular value for compounds which are
given for weeks or months. Such compounds are usually incorporated in
disease-preventive or growth-promoting types of products. In this test, a
series of dosages covering a wide
range are continually administered
and are started during the growth
phase. The minimum length is ninety
days, but it may be extended to the
normal market age of the animal. Sufficient numbers of individually housed
animals of both sexes are used in each
dose level to permit a valid statistical
evaluation of effects on growth and
feed consumption. During the test,
hematologic studies are made periodically and a number of other biochemical tests may be conducted. All animals dying during the test are examined, and at the end of the test all
are killed and examined for gross
pathology. Samples of approximately
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thirty tissues are taken for microscopic
evaluation by a pathologist. The product is considered to be safe for the
animals if the maximum no-effect
dose is at least three times the usedose of the compound.
Because the safety for man is part
of the evaluation, the same type of
test is also conducted in rats or mice
and dogs. These tests are ninety days
in duration. If the maximum no-effect
dose and the maximum tolerated dose
are approximately the same in the two
species, toxicologists assume that man
can detoxify the compound in approximately the same manner and a
potential hazard for man can be established.
During this time, biochemists have
also been at work to determine whether the compound is metabolized by
the animals and, if so, what the principal metabolites are. A method of analysis for these must be developed so
that the amount of residue in the major consumable tissues can be determined. The sensitivity of the method
depends on the toxicity of the drug. A
drug which has a wide margin of
safety, i.e., a low order of toxicity,
does not require as sensitive a method, while one with a narrow margin
of safety requires greater sensitivity.
A rule of thumb in our laboratory is
sensitivity and accuracy to less than
0.1 ug per gram of tissue. Methods 10
to 100 times this sensitivity are in use
today. The sophistication of the method usually involves some type of chromatography and the use of sensitive
electronic devices, e.g., gas chromatograph, spectrophotometer, polarograph. When the method is available,
then the rate of disappearance of the
residue following the withdrawal · of

the drug is established. This provides
evidence for determining how long
before slaughter for human consumption the drug must be withdrawn. If
applicable, the occurrence of the residue in milk or eggs is also made and
if any is found, the product can be
used only in such a manner that the
milk or eggs containing residue will
not be consumed by man. In this manner, man is protected from a possible
hazard in his food.
If a residue exists and it is desirable
to give the product until slaughter of
the animal for human food, then present FDA requirements are that the
compound must be subjected to a
chronic toxicity study in rats or mice
and dogs. In our laboratory, in addition, we conduct such tests in chickens. Except for dogs, the size of each
treatment group must be large enough
to permit adequate data at the end of
the test for statistical evaluation. A
current test was started with a total of
1,200 mice and another test with 400
rats, each individually caged. The dosages used may be governed by the
highest tissue residue found while the
animals are receiving medication. The
residue in meat may be considered to
be safe for man if 100 times its quantity is safe for the test animals when
given throughout the two years of test.
Food consumption is measured
throughout the test because it measures the dosage since the compound is
incorporated in the feed. Body weights
are taken at weekly or biweekly intervals. Periodic hematologic examinations are performed and enzyme
studies may be conducted. Each animal which dies must be examined at
post-mortem and tissues taken for histologic examination . At the termina-
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tion of the test, all of the survivors are
killed, examined for gross pathology,
and tissues from a proportion are subjected to microscopic examination by
a pathologist. This type of test also
determines whether the compound
may be cancer-inducing in the rodent.
The fourth team involved in the development of a drug is the clinical
team. Before the drug can be cleared,
it must be subjected to testing in the
field. This cannot be done until effectiveness has been shown, safety
studies have been completed, and the
tissue residues and the rate of their
depletion established to the satisfaction of the FDA. Thus, when the animals go to market, there will be no
potential hazard for man. The purpose of this testing is to determine
both the safety and effectiveness of
the use dose under diverse conditions.
To accomplish this, the testing is carried out in about half a dozen different geographic locations during different seasons of the year. A considerable
number of animals are used at each
location and in the different seasons.
With broiler chickens, this may total
to several hundred thousand birds.
During the course of these tests, periodic examinations are made of the
group undergoing medication for effectiveness of the drug and for any
unpredicted reactions. If the animals
are slaughtered for human consumption, they are followed through the
packing house and the carcasses examined. If the product is a disease
preventive, it must be shown that the
test animals were exposed to the disease. A product successful in these

tests should be successful on the market as far as safety and effectiveness
are concerned.
The extensive and intensive work
required for the development of a
product for market clearly shows why
a team approach is the only practical
approach. Judicious management procedures must coordinate and correlate
the many scientific disciplines involved. One important aspect not previously mentioned is the necessity of
clear, concise, well-organized and
readily understandable reports of the
testing so that others, particularly the
FDA officials, can easily conclude
whether the product is safe and effective. It should be readily understood that a number of years are involved in completing the development
of a drug. If no serious difficulties are
encountered, the shorter-term phases
of development can b e completed in
approximately two and a half years.
With luck and good planning, the entire testing takes four years, but our
experience has shown that five years
are frequently required.
The whole procedure of drug development is very challenging. When
it is accomplished, those involved derive much satisfaction, particularly
when the marketing personnel are successful in selling the product and the
need of a customer is fulfilled. One
also has the satisfaction of knowing
that he has made a contribution to the
food supply for man, a contribution
which by modern methods of evaluation will not add to the potential hazards encountered in man's daily life.
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